PMID- 26637048
OWN - NLM
STAT- MEDLINE
DCOM- 20160829
LR  - 20221207
IS  - 1473-4877 (Electronic)
IS  - 0300-7995 (Linking)
VI  - 32
IP  - 2
DP  - 2016
TI  - Efficacy and tolerability of switching therapy to vortioxetine versus other 
      antidepressants in patients with major depressive disorder.
PG  - 351-66
LID - 10.1185/03007995.2015.1128404 [doi]
AB  - OBJECTIVES: To assess the relative efficacy and tolerability of vortioxetine 
      against different antidepressant monotherapies in patients with major depressive 
      disorder (MDD) with inadequate response to selective serotonin reuptake inhibitor 
      (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI) therapy. METHODS: A 
      systematic search was conducted for monotherapy studies in patients with MDD with 
      inadequate response to first-line therapy. Treatments included SSRIs, SNRIs, and 
      other antidepressants. Identified studies underwent a three-stage screening/data 
      extraction process and critical appraisal. Adjusted indirect treatment 
      comparisons (ITCs) on systematic literature review outputs were made using 
      Bucher's method, comparing remission rates and withdrawal rates due to adverse 
      events (AEs). RESULTS: Of 27 studies meeting the inclusion criteria, a few 
      studies were of high quality according to the National Institute of Health and 
      Care Excellence checklist. Three studies contributed to an evidence network for 
      quantitative assessment comparing vortioxetine with agomelatine, sertraline, 
      venlafaxine XR, and bupropion SR. Vortioxetine had a statistically significantly 
      higher remission rate than agomelatine (risk difference [RD]: -11.0% [95% CI: 
      -19.4; -2.6]), and numerically higher remission rates than sertraline (RD: -14.4% 
      [95% CI: -29.9; 1.1]), venlafaxine (RD: -7.20% [95% CI: -24.3; 9.9]), and 
      bupropion (RD: -10.70% [95% CI: -27.8; 6.4]). Withdrawal rates due to AEs were 
      statistically significantly lower for vortioxetine than sertraline (RD: 12.1% 
      [95% CI: 3.1; 21.1]), venlafaxine XR (RD: 12.3% [95% CI: 0.8; 23.8]), and 
      bupropion SR (RD: 18.3% [95% CI: 6.4; 30.1]). CONCLUSIONS: The current systematic 
      literature review found a few high quality switch studies assessing monotherapies 
      in patients with MDD with inadequate response to SSRI/SNRIs. ITCs indicated that 
      switching to vortioxetine leads to numerically higher remission rates compared 
      with other antidepressants. Vortioxetine is a well tolerated treatment, showing 
      statistically lower withdrawal rates due to AEs compared with other 
      antidepressants. Vortioxetine is a relevant therapeutic alternative in patients 
      experiencing inadequate response to prior SSRI or SNRI therapy.
FAU - Brignone, Melanie
AU  - Brignone M
AD  - a a Lundbeck SAS , Paris , France.
FAU - Diamand, Francoise
AU  - Diamand F
AD  - a a Lundbeck SAS , Paris , France.
FAU - Painchault, Caroline
AU  - Painchault C
AD  - b b Keyrus Biopharma , Levallois Perret , France.
FAU - Takyar, Shweta
AU  - Takyar S
AD  - c c Parexel International , Chandigarh , India.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PT  - Systematic Review
PL  - England
TA  - Curr Med Res Opin
JT  - Current medical research and opinion
JID - 0351014
RN  - 0 (Antidepressive Agents)
RN  - 0 (Piperazines)
RN  - 0 (Serotonin Uptake Inhibitors)
RN  - 0 (Sulfides)
RN  - 3O2K1S3WQV (Vortioxetine)
SB  - IM
MH  - Antidepressive Agents/*therapeutic use
MH  - Depressive Disorder, Major/*drug therapy
MH  - Humans
MH  - Piperazines/*therapeutic use
MH  - Selective Serotonin Reuptake Inhibitors/therapeutic use
MH  - Sulfides/*therapeutic use
MH  - Vortioxetine
OTO - NOTNLM
OT  - Indirect treatment comparison
OT  - Major depressive disorder
OT  - Switch study
OT  - Systematic literature review
OT  - Vortioxetine
EDAT- 2015/12/05 06:00
MHDA- 2016/08/30 06:00
CRDT- 2015/12/05 06:00
PHST- 2015/12/05 06:00 [entrez]
PHST- 2015/12/05 06:00 [pubmed]
PHST- 2016/08/30 06:00 [medline]
AID - 10.1185/03007995.2015.1128404 [doi]
PST - ppublish
SO  - Curr Med Res Opin. 2016;32(2):351-66. doi: 10.1185/03007995.2015.1128404.